Table 1.
Mesenchymal stem cell extracellular vesicle (MSCEV) treatment approaches in clinical trials. AMSCEV, adipose-derived MSCEV; BMMSCEV, bone marrow-derived MSCEV; UMSCEV, urine-derived MSCEV; CKD, chronic kidney disease.
| Condition | Injured/Diseased Tissue | Treatment Approach | Trial Phase |
|---|---|---|---|
| Healthy | Injured lungs | Aerosol-based inhalation of AMSCEV (1 or 2 or 3 × 108 particles/3 mL) | I [64] |
| Osteoarthritis | Injured cartilage | Osteochondral explant from arthroplasty treatment with AMSCEVs | |
| Bronchopulmonary dysplasia | Chronic lung disease | Intravenous infusion of BMMSCEVs (20 or 60 or 200 pmol phospholid/kg body weight) | |
| COVID-19 | Lungs (pneumonia) | Aerosol inhalation of AMSCEVs (2 × 108 particles/3 mL) for 5 days | |
| Dystrophic epidermolysis bullosa | Skin | Local administration of allogenic BMMSCEVs | II [64] |
| Acute ischemic stroke | Injured brain | Stereotaxis-based administration of miR-124 (200 µg total EV protein) enriched MSCEVs | |
| Kidney | CKD | Injection of allogenic UMSCEVs (100 µg total EV protein/kg/dose) | II/III [96] |